Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
NCT00117572
Completed
The combined use of chemotherapeutic drugs with radiation has proven to be effective in improving overall survival and local control among patients with locally advanced head and neck cancer. Induction chemotherapy given before receiving local treatment has been shown to reduce the rate of distant failure. Many drugs have been found to prevent tumor cells from growing or dividing, although it has yet to be determined which agent, or specific combination of agents, is most effective in treating h... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/06/2018
Locations: USC University of Southern California Keck School of Medicine, Los Angeles, California +25 locations
Conditions: Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Nasal Cavity, Paranasal Sinus Neoplasms, Cancer of the Oral Cavity
Register for Updates
Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer
NCT01091454
Completed
This phase II trial studies how well brostallicin and cisplatin work in treating patients with breast cancer that has spread to other parts of the body (metastatic) and does not have estrogen receptors, progesterone receptors, or large amounts of human epidermal growth factor receptor 2 (HER2) on its cells (triple-negative). Drugs used in chemotherapy, such as brostallicin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them fro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/06/2018
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +265 locations
Conditions: Triple-negative Breast Cancer
Register for Updates
A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer
NCT00001426
Completed
A supra-additive cytotoxic effect was seen when CAI and paclitaxel were given to human ovarian cancer cells sequentially in tissue culture. We have demonstrated that CAI given for 8 days followed by paclitaxel is reasonably well tolerated and that paclitaxel administration causes a dose-dependent increase in CAI plasma concentration. CAI is a cytostatic drug and continuous exposure is needed. This study will evaluate the combination of continuously administered CAI with three-weekly paclitaxel.
Gender:
FEMALE
Ages:
All
Trial Updated:
04/04/2018
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Ovarian Neoplasm
Register for Updates
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
NCT00949650
Completed
This randomised, open label phase III trial will be performed in patients with adenocarcinoma of the lung with tumours harbouring an Epidermal Growth Factor Receptor activating mutation. The objectives of the trial are to compare the efficacy of single agent BIBW 2992, Arm A, with Pemetrexed/Cisplatin chemotherapy, Arm B, as first line treatment for this group of patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/09/2018
Locations: Highlands Oncology Group, Fayetteville, Arkansas +132 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
Register for Updates
Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy
NCT02492360
Withdrawn
This study targets patients with cisplatin-induced peripheral neuropathy and will allow us to: a) study peripheral neuropathy in diverse human sensory neurons in ways that were not possible previously; b) gain insight on druggable targets to treat or prevent this devastating side effect of chemotherapy; c) provide a human cellular model that can be used for screening of drugs to determine if they are neurotoxic. The combination of patient information and in vitro measurements provides a highly r... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/27/2018
Locations: IU Simon Cancer Center, Indianapolis, Indiana
Conditions: Peripheral Nervous System Diseases, Testicular Neoplasms
Register for Updates
Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer
NCT00369122
Completed
This phase II trial is studying how well giving bevacizumab together with radiation therapy and cisplatin works in treating patients with previously untreated locally advanced cervical cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of cervical cancer by blocking blood flo... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
02/21/2018
Locations: Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California +105 locations
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7
Register for Updates
A Study of LY2801653 in Advanced Cancer
NCT01285037
Completed
Part A- The purpose of this study is to determine a safe dose of LY2801653 to be given to participants with advanced cancer and to determine any side effects that may be associated with LY2801653 in this participant population. Efficacy measures will be used to assess the activity of LY2801653. Part B- The dose determined in Part A will be used along with efficacy measures to assess the activity of LY2801653 in participants with adenocarcinoma of the colon or rectum, head and neck squamous cell... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2018
Locations: Arizona Cancer Center, Tucson, Arizona +6 locations
Conditions: Cancer
Register for Updates
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
NCT01005329
Completed
This phase II trial studies the side effects of giving intensity-modulated radiation therapy together with cisplatin and bevacizumab followed by carboplatin and cisplatin and to see how well they work in treating patients who have undergone surgery for high-risk endometrial cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, carboplatin,... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/15/2018
Locations: Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California +40 locations
Conditions: Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Register for Updates
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
NCT01384799
Completed
This is a phase I dose escalation study of CUDC-101 in combination with concurrent cisplatin and radiation therapy in patients with locally advanced head and neck cancer. CUDC-101 is a multi-targeted agent designed to inhibit epidermal growth factor receptor (EGFR), human epidermal growth factor receptor Type 2 (Her2) and histone deacetylase (HDAC). The study is designed to establish the safety, tolerability and maximum tolerated dose (MTD) of CUDC-101 when administered in combination with concu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/15/2018
Locations: Stanford Cancer Center, Stanford, California +6 locations
Conditions: Head and Neck Cancer
Register for Updates
A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma
NCT03081039
Withdrawn
Compare the efficacy of adjuvant chemotherapy with Cisplatin or Carboplatin and Gemcitabine versus Gemcitabine in patients with resected or ablated intra-hepatic cholangiocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/15/2018
Locations: University of Louisville, Louisville, Kentucky
Conditions: Intrahepatic Cholangiocarcinoma
Register for Updates
Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma
NCT00257816
Completed
There will be approximately 14,000 new patients with invasive cervical cancer diagnosed in the United States in 2003 with about 4,000 deaths from this disease. This accounts for approximately 17% of all deaths due to gynecologic cancers. Radiation has been the primary treatment modality for locoregionally advanced cervical cancer. Recent trials of concomitant systemic cisplatin chemotherapy and radiation have shown high response rates (RR) with improvements in durable remissions and overall surv... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/01/2018
Locations: Chao Family Comprehensive Cancer Center, Orange, California
Conditions: Cervical Cancer
Register for Updates
(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
NCT01936974
Terminated
To evaluate progression-free survival with two chemotherapy regimens on platinum-resistant/refractory ovarian and peritoneal carcinoma
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/22/2018
Locations: Western Regional Medical Center, Goodyear, Arizona
Conditions: Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
Register for Updates